News

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...
Experts refute that claim. Mario Tama/Getty Share Gov. JB Pritzker on Wednesday signed an executive order to restrict the mass collection and sharing of autism-related data for Illinois residents ...
President Donald Trump’s April 2025 executive order titled ... To read the order without that context is to miss its meaning entirely. It does several things at once, each reinforcing the ...
By Carl Zimmer and Emily Anthes President Trump signed an executive order on Monday evening to further restrict experiments on pathogens and toxins that could make them more harmful. For over a ...
Public TV and radio stations across the U.S. are in a state of limbo after President Donald Trump signed an executive order Thursday night that seeks to terminate federal funding to National ...
In President Donald Trump’s latest push to bring pharmaceutical manufacturing to the U.S., a new executive order tasks the FDA with reducing regulatory hurdles for domestic producers while ...
(Reuters) -U.S. President Donald Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharmaceutical plants in the country, as part of new regulations to ...
PRESIDENT DONALD TRUMP SIGNED AN EXECUTIVE ORDER MAY 1ST, BLOCKING ANY FEDERAL FUNDING TO PBS AND NPR, CITING IDEOLOGICAL BIAS. THE CORPORATION FOR PUBLIC BROADCASTING ANNOUNCED TUESDAY FUNDING ...
While the executive order accuses these jurisdictions of “non-compliance” with federal immigration enforcement, Fleming said it is not the jurisdictions’ legal role to participate in ...
16 WAPT BROOKLYN JOYNER SPENT THE MORNING AT MISSISSIPPI PUBLIC BROADCASTING, AS THEY SAY, EXECUTIVE ORDER IS LEAVING THEM IN A PLACE OF UNCERTAINTY. >> WORKFLOW CONTINUES AS USUAL HERE AT THE ...
President Donald Trump signed an executive order on Monday to encourage domestic prescription drug manufacturing and cut down on the time it takes to approve U.S. pharmaceutical plants.